Evidence map›Paper›PMID 25165025›Full record

ArticleClinical and vaccine immunology : CVI2014

Use of S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-monomethoxy polyethylene glycol as an adjuvant improved protective immunity associated with a DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus in mice.

Angello Retamal-Díaz, Roberto Riquelme-Neira, Darwin Sáez, Alejandra Rivera, Pablo Fernández, Alex Cabrera, Carlos A Guzmán, Angel Oñate

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Frontiers in cellular and infection microbiology · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Angello Retamal-DíazMolecular Immunology Laboratory, Department of Microbiology, Faculty of Biological Sciences, Universidad de Concepción, Concepción, Chile.
Roberto Riquelme-NeiraMolecular Immunology Laboratory, Department of Microbiology, Faculty of Biological Sciences, Universidad de Concepción, Concepción, Chile.
Darwin SáezMolecular Immunology Laboratory, Department of Microbiology, Faculty of Biological Sciences, Universidad de Concepción, Concepción, Chile.
Alejandra RiveraMolecular Immunology Laboratory, Department of Microbiology, Faculty of Biological Sciences, Universidad de Concepción, Concepción, Chile.
Pablo FernándezMolecular Immunology Laboratory, Department of Microbiology, Faculty of Biological Sciences, Universidad de Concepción, Concepción, Chile.
Alex CabreraDepartment of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Carlos A GuzmánDepartment of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Angel OñateMolecular Immunology Laboratory, Department of Microbiology, Faculty of Biological Sciences, Universidad de Concepción, Concepción, Chile aonate@udec.cl.
University of Concepción · CLHelmholtz Centre for Infection Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was conducted to evaluate the immunogenicity and protective efficacy of a DNA vaccine encoding Brucella abortus Cu,Zn superoxide dismutase (SOD) using the Toll-like receptor 2/6 agonist S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-monomethoxy polyethylene glycol (BPPcysMPEG) as an adjuvant. Intranasal coadministration of BPPcysMPEG with a plasmid carrying the SOD-encoding gene (pcDNA-SOD) into BALB/c mice elicited antigen-specific humoral and cellular immune responses. Humoral responses were characterized by the stimulation of IgG2a and IgG1 and by the presence of SOD-specific secretory IgA in nasal and bronchoalveolar lavage fluids. Furthermore, T-cell proliferative responses and increased production of gamma interferon were also observed upon splenocyte restimulation with recombinant SOD. Cytotoxic responses were also stimulated, as demonstrated by the lysis of RB51-SOD-infected J774.A1 macrophages by cells recovered from immunized mice. The pcDNA-SOD/BPPcysMPEG formulation induced improved protection against challenge with the virulent strain B. abortus 2308 in BALB/c mice over that provided by pcDNA-SOD, suggesting the potential of this vaccination strategy against Brucella infection.

Indexed as

Adjuvants, ImmunologicAdministration, IntranasalAnimalsAntibodies, BacterialBacterial ProteinsBronchoalveolar Lavage FluidBrucella abortusBrucella VaccineBrucellosisCell ProliferationCytotoxicity Tests, ImmunologicDisease Models, AnimalFemaleImmunoglobulin A, SecretoryImmunoglobulin GInterferon-gammaAdjuvants, ImmunologicAntibodies, BacterialBacterial ProteinsBrucella VaccineImmunoglobulin A, SecretoryImmunoglobulin GInterferon-gammaPolyethylene GlycolsSuperoxide DismutaseTlr2 protein, mouseTlr6 protein, mouseToll-Like Receptor 2Toll-Like Receptor 6Vaccines, DNA

Identifiers

PMID25165025
PMCPMC4248768
OpenAlexW2143602029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.